Biologicals

Plant vaccines

Vaccines are effective means of reducing the disease burden of infectious diseases in developing countries. To ensure the widest availability of these vaccines in poor countries, approaches are needed with lower production costs and less need of medical personnel to administer the vaccines. A promising avenue is the development of plant-derived vaccines, which can be administered orally or to other mucosal surfaces. Plants are able to produce different classes of proteins of pharmaceutical significance at a high yield, leading to potentially inexpensive products. Oral administration is important as it diminishes the need for needles and syringes which require highly trained immunization staff.


RELATED LINKS

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



NEW PUBLICATIONS

UPCOMING EVENTS


  • WHO Informal Consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products including biosimilars, Seoul, Republic of Korea, 27-28 April 2017
  • Working Group meeting on revision of WHO TRS 941, Annex 5: WHO biosafety risk assessment and Guidelines for the production and quality control of human influenza pandemic vaccines, Geneva, Switzerland, 9-10 May 2017
  • Working group meeting on Hepatitis E Vaccine, Geneva, Switzerland, 11-12 May 2017

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971